| Brief Title | Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
|---|---|
| Official Title | A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| Principal Investigator | Vokes, Everett |
| Brief Summary | A study in patients with metastatic or recurrent squamous cell cancer of the head and neck to evaluate the effectiveness of Nivolumab plus Ipilumumab vs. Nivolumab alone (CheckMate 714) |
| Gender | All |
| Ages | 18 Years |
| Enrollment | 315 |
| Accepts Healthy Volunteers | No |
| Lead Sponsor | Bristol-Myers SquibbIndustry |
| Collaborator | |
| Study Design | |
| Study Phase | Phase 2 |
| Study Type | Interventional |
| Contact Name | |
| Contact Phone | 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) |
| Condition | Head and Neck Cancer |